Revive Rx

• Pharmacy Profile Name: Revive Rx LLC dba Revive Rx Pharmacy
• Website: reviverx.com
• Address: 3831 Golf Dr A, Houston, TX 77018
• Co-Founders: Brigham Buhler; Aaron Schneider, PharmD (Chief of Pharmacy / Co-Owner)
• Pharmacy Type: 503A compounding and mail-order pharmacy
• GLP-1 Products: Tirzepatide (with Vitamin B6), Semaglutide, Sermorelin, peptides
• Licensed: 45 states + Puerto Rico
• Sister Company: Ways2Well (functional and regenerative care clinic)

About the Pharmacy

Brigham Buhler is the founder of Ways2Well, a functional and regenerative care clinic, and its sister company, ReviveRx: a pharmacy focusing on health, wellness, and restorative medicine. Aaron M. Schneider serves as Chief of Pharmacy and Co-Owner.

ReviveRX is a licensed mail-order pharmacy that specializes in both commercially available and compounded medications, with services available nationwide and licensed in 45 states and Puerto Rico.

ReviveRX’s multidisciplinary team includes pharmacists, a microbiologist, and a PhD chemist, operating in USP-certified clean rooms with a broad portfolio of compounded formulations across hormones, weight management, wellness, peptides, sexual wellness, and more. The pharmacy offers a dedicated territory manager and representative model for clinic partners, with a 3-day turnaround on direct-to-patient delivery and a unified ordering dashboard.

GLP-1 Compounding

Revive Rx compounded tirzepatide and semaglutide extensively during the FDA shortage era, and remains positioned as a GLP-1 compounding pharmacy. Eli Lilly’s complaint alleges that Revive dispensed mass quantities of its own compounded tirzepatide products — specifically fixed-dose combinations of tirzepatide and vitamin B6 in regular and large-volume vials — rather than bespoke patient-specific formulations. Given the post-shortage regulatory environment as of March 2026, patients should confirm directly with Revive Rx what GLP-1 formulations remain legally available under their clinical circumstances.

Type of Pharmacy

Revive Rx is a 503A state-licensed compounding and mail-order pharmacy. No PCAB or NABP accreditation was found in publicly available records as of March 2026.

Regulatory History — Multiple Actions:

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

May 2023 — Class II Recall: Revive Rx voluntarily initiated a Class II recall of Tirzepatide 10 mg/0.5 mL Sterile Solution (2 mL vials) due to sub-potent drug.

April 2024 — Class I Recall: Revive Rx voluntarily recalled 751 units of Tirzepatide 10 mg/0.5 mL Sterile Solution (2 mL multi-dose vials) on April 20, 2024, due to a label mix-up — product labeled as tirzepatide was found to contain testosterone cypionate. The FDA classified this as a Class I recall, the most serious category, indicating that use of the mislabeled product could cause serious health effects or death. The recalled product was distributed nationally.

FDA Form 483 — February 2025: FDA investigators documented multiple microbial contamination events across production runs at the Houston facility, including Staphylococcus species recovered from a hood during tirzepatide production in December 2024, Actinomyces species recovered during testosterone cypionate production in October 2024, and ten separate contamination recoveries in the ISO 7 hazardous negative cleanroom in August 2023 — including Neisseria, Penicillium citrinum, Cladosporium, Streptococcus, and Micrococcus species — that were not investigated, not subjected to additional sampling, and not addressed with robust cleaning. Additional findings included inadequate environmental monitoring practices and improper aseptic processing transfers exposing sterile product to uncontrolled environments.

Texas Board of Pharmacy and Other State Actions: Eli Lilly’s lawsuit against Revive alleges that, at least in the past five years, the FDA, Texas Board of Pharmacy, and other regulators have cited Revive for violations of safety, sanitation, and licensing requirements, and that Revive has recalled compounded tirzepatide drugs on multiple occasions — including the sub-potent recall and the testosterone cypionate mislabeling — and has received customer complaints about watered-down and ineffective medication.

Eli Lilly Lawsuit: Eli Lilly filed suit against Revive Rx for unauthorized compounding of tirzepatide at mass scale, alleging both intellectual property violations and patient safety risks, with the suit proceeding in the Southern District of Texas.

States Licensed In

ReviveRX is licensed in 45 states and Puerto Rico.

Telehealth Providers They Work With

Revive Rx operates primarily through a B2B clinic and provider partnership model rather than direct consumer telehealth platforms. Its sister company, Ways2Well, is among the practices that have used Revive Rx as a compounding partner. The pharmacy offers dedicated territory managers and a digital ordering dashboard for clinic partners, supporting account setup, ordering, and ongoing clinical communications. No specific named consumer-facing telehealth platform partnerships were confirmed in public records as of March 2026.

Pricing from Reviews

ReviveRX positions its pricing as competitive, with fair pricing and quick shipping emphasized in partner reviews. The pharmacy accepts HSA/FSA and offers price matching against other pharmacy solutions. Consumer-facing GLP-1 pricing is not publicly listed. Clinic partners access pricing through account onboarding.

Overall Reviews

Clinic and provider reviews for Revive Rx on its own website are consistently positive, citing fast turnaround, product selection, and responsive account management. However, Eli Lilly’s lawsuit references customer complaints about Revive’s compounded tirzepatide products being watered-down and ineffective — consistent with the 2023 sub-potency recall — reflecting a gap between provider-facing satisfaction and some patient-level outcomes.

The dual recall history — sub-potent tirzepatide in 2023 and the wrong-drug mislabeling of testosterone cypionate as tirzepatide in 2024 — combined with the February 2025 FDA Form 483 documenting recurring microbial contamination across multiple production runs represents one of the more serious cumulative quality records in this directory series.